Liposome Company, Inc. - LIPO- Profile

The Liposome Company, Inc. is a biopharmaceutical company that discovers, develops, manufactures and markets proprietary lipid and liposome based pharmaceutical products. The products of the company are used for the treatment of cancer and other related life-threatening illnesses. The products of the company include drug delivery vehicles and novel pharmaceuticals utilizing modulated cell signalling and bioactive lipids. The company's product ABELCET treats many types of systemic fungal infections such as candidiasis, aspergillosis and cryptococcal meningitis which are found mainly in cancer patients, organ and bone marrow transplant recipients and people infected with AIDS. Other products of the company include EVACET (Liposomal Doxorubicin) and TLC ELL 12 (Liposomal Ether Lipid). The company also undertakes contract based research programs. These research programs include Bromotaxol (hydrophobic derivative of paclitaxel), Ceramides and Sphingosines and Gene therapy. International markets for the company's product include Canada, the United Kingdom and Western Europe. The company had incurred aggregate costs of approximately $150,000 towards year 2000 issues till date. On March 6, 2000, the company entered into a definite merger agreement under which Elan Corporation plc will acquire the company.